Diffuse Large B Cell Lymphoma
Conditions
Keywords
Curative effect evaluation, Adverse reactions, Clinical characteristics, PR, PFS, OS
Brief summary
To explore the clinical features and efficacy evaluation of large b-cell lymphoma in old age.
Detailed description
The results of the analysis of the treatment of large b-cell lymphoma in old age were analyzed, and the treatment of large B cell lymphoma was provided.
Interventions
DRUG(R)-CHOP regimen
(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
DRUG(R)-CVP regimen
The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
Sponsors
Mingzhi Zhang
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Above 70 years old，Pathology proved to be diffuse large B cell lymphoma，Estimated survival time \> 3 months，None of chemotherapy contraindication;At least one measurable lesion according to RECIST;None of other serious diseases;Patients could be followed up;None of other relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy except anti-bone metastasis therapy and other symptomatic treatments. volunteers who signed informed consent.
Exclusion criteria
* Currently undergoing chemotherapy, radiotherapy and targeted therapy (received chemotherapy within 3 weeks, received radiotherapy within 2 weeks, or has not recovered from any previous treatment of acute toxicity);Patients with uncontrolled medical problems (including active infection, uncontrolled diabetes, severe heart, liver, kidney dysfunction and interstitial pneumonia, etc.); Pregnant or lactating women;Serious medical illness likely to interfere with participation;Chemotherapy contraindication such as cachexia; patients with other malignancies previously;Serious infection;The evidence of peripheral nervous disorder or dysphrenia; patients estimated to be unsuitable by investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | up to end of follow-up-phase(approximately 24 months) | Progression-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | up to the date of death (approximately 5 years) | overall survival |
| disease control rate | every 6 weeks,up to completion of treatment(approximately 18 weeks )] | disease control rate |
| objective remission rate | every 6 weeks,up to completion of treatment(approximately 18 weeks )] | objective remission rate |
Countries
China
Contacts
Primary ContactMingzhi zhang, Pro,Dr
Backup ContactMingzhi zhang
Outcome results
None listed